AstraZeneca Launches Zegfrovy Lung Cancer Drug in US
AstraZeneca announced the U.S. launch of Zegfrovy (sunvozertinib), indicated for adults with locally advanced or metastatic non-small cell lung cancer carrying EGFR exon 20 insertions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AstraZeneca Launches ZEGFROVY in the US for NSCLC
AstraZeneca said ZEGFROVY is available in the US for adults with EGFR exon 20 insertion-mutated NSCLC after platinum chemotherapy. The FDA granted accelerated approval based on a 46% confirmed response rate in WU-KONG1B.